Alexander O. Schuth Sells 15,558 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the sale, the insider now directly owns 178,066 shares in the company, valued at approximately $5,325,954.06. This trade represents a 8.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $28.45 on Friday. The firm has a fifty day moving average of $28.20 and a two-hundred day moving average of $23.91. The stock has a market capitalization of $4.09 billion, a price-to-earnings ratio of -10.31 and a beta of 1.40. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the company posted ($0.72) EPS. As a group, research analysts forecast that Denali Therapeutics Inc. will post -2.66 EPS for the current fiscal year.

Institutional Trading of Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its holdings in shares of Denali Therapeutics by 879.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock valued at $48,000 after buying an additional 1,847 shares during the period. CWM LLC grew its holdings in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares during the period. Quest Partners LLC acquired a new position in shares of Denali Therapeutics in the 3rd quarter valued at $73,000. Headlands Technologies LLC acquired a new position in shares of Denali Therapeutics in the 1st quarter valued at $88,000. Finally, Assetmark Inc. grew its holdings in shares of Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after buying an additional 580 shares during the period. Institutional investors own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DNLI. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Denali Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group lifted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st. JPMorgan Chase & Co. decreased their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.90.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.